News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Banyu Pharmaceutical Co. And Ono Pharmaceutical Company, Ltd. Begins Phase III Clinical Trials Of A DPP-4 Inhibitor For Type 2 Diabetes Patients
August 14, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Banyu Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd. will begin Phase III Clinical Trial of Sitagliptin (Development Code: MK-0431/ONO-5435) in Japan.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Asia
MORE ON THIS TOPIC
Rare diseases
BridgeBio Builds Case for Early 2027 Launch of Dystrophy Drug
March 12, 2026
·
2 min read
·
Tristan Manalac
Clinical research
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders
March 12, 2026
·
3 min read
·
Tristan Manalac
Insights
From Two Trials to One, Sponsors Face a Higher Standard
March 12, 2026
·
1 min read
·
Jennifer C. Smith-Parker
China
Lilly Pumps $3B Into China To Boost Supply of Weight Loss Pill
March 11, 2026
·
2 min read
·
Tristan Manalac
